RGRX — RegeneRx Biopharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $1.33m
- $0.08m
Annual cashflow statement for RegeneRx Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.99 | -1.4 | -1.52 | -1.6 | -1.73 |
| Depreciation | |||||
| Non-Cash Items | 0.925 | 0.375 | 0.494 | 0.577 | 0.748 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.178 | -0.11 | 0.022 | 0.03 | 0.039 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -0.888 | -1.14 | -1.01 | -0.99 | -0.941 |
| Financing Cash Flow Items | -0.086 | 0 | -0.002 | 0 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.944 | 1.54 | 0.795 | 1.79 | 0 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.056 | 0.403 | -0.212 | 0.804 | -0.941 |